{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:44:23Z","timestamp":1792723463961,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04357-x","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:43:52Z","timestamp":1776872632000},"page":"4849-4862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive model for clear cell renal cell carcinoma: a novel model integrating sunitinib resistance and prognosis related genes and clinical factors"],"prefix":"10.1007","volume":"28","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2209-893X","authenticated-orcid":false,"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"7","key":"4357_CR1","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/cac2.12428","volume":"43","author":"L Luo","year":"2023","unstructured":"Luo L, Wei D, Pan Y, Wang QX, Feng JX, Yu B, et al. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR. Cancer Commun. 2023;43(7):808\u201333.","journal-title":"Cancer Commun"},{"key":"4357_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.972227","volume":"13","author":"K Zheng","year":"2022","unstructured":"Zheng K, Gao L, Hao J, Zou X, Hu X. An immunotherapy response prediction model derived from proliferative CD4(+) T cells and antigen-presenting monocytes in ccRCC. Front Immunol. 2022;13:972227.","journal-title":"Front Immunol"},{"key":"4357_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/15330338241275403","volume":"23","author":"S Boussios","year":"2024","unstructured":"Boussios S, Ovsepian SV. Exosomes in renal cell cancer: diagnostic and therapeutic nanovehicles. Technol Cancer Res Treat. 2024;23:15330338241275403.","journal-title":"Technol Cancer Res Treat"},{"key":"4357_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010034","author":"L Meng","year":"2023","unstructured":"Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, et al. Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma. Cells. 2023. https:\/\/doi.org\/10.3390\/cells13010034.","journal-title":"Cells"},{"issue":"11","key":"4357_CR5","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.21873\/anticanres.16675","volume":"43","author":"H Aweys","year":"2023","unstructured":"Aweys H, Lewis D, Sheriff M, Rabbani RD, Lapitan P, Sanchez E, et al. Renal cell cancer - insights in drug resistance mechanisms. Anticancer Res. 2023;43(11):4781\u201392.","journal-title":"Anticancer Res"},{"issue":"25","key":"4357_CR6","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","volume":"40","author":"WK Rathmell","year":"2022","unstructured":"Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO Guideline. J Clin Oncol. 2022;40(25):2957\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4357_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","volume":"24","author":"JE Brown","year":"2023","unstructured":"Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2023;24(3):213\u201327.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4357_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1517\/14728214.2015.1047761","volume":"20","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Albiges L, Escudier B. Emerging tyrosine kinase inhibitors for the treatment of renal cancer. Expert Opin Emerg Drugs. 2015;20(3):379\u201392.","journal-title":"Expert Opin Emerg Drugs"},{"key":"4357_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100929","volume":"67","author":"J Jin","year":"2023","unstructured":"Jin J, Xie Y, Zhang JS, Wang JQ, Dai SJ, He WF, et al. Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Drug Resist Updat. 2023;67:100929.","journal-title":"Drug Resist Updat"},{"issue":"8","key":"4357_CR10","doi-asserted-by":"publisher","first-page":"e515","DOI":"10.1016\/S2589-7500(23)00095-X","volume":"5","author":"CP Gui","year":"2023","unstructured":"Gui CP, Chen YH, Zhao HW, Cao JZ, Liu TJ, Xiong SW, et al. Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study. Lancet Digit Health. 2023;5(8):e515\u201324.","journal-title":"Lancet Digit Health"},{"issue":"3","key":"4357_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/cncr.35037","volume":"130","author":"BN Schmeusser","year":"2024","unstructured":"Schmeusser BN, Patil DH, Nicaise EH, Armas-Phan M, Nabavizadeh R, Narayan VM, et al. 2018 Leibovich prognostic model for renal cell carcinoma: performance in a large population with special consideration of Black race. Cancer. 2024;130(3):453\u201366.","journal-title":"Cancer"},{"issue":"4","key":"4357_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.eururo.2016.05.034","volume":"71","author":"WP Parker","year":"2017","unstructured":"Parker WP, Cheville JC, Frank I, Zaid HB, Lohse CM, Boorjian SA, et al. Application of the stage, size, grade, and necrosis (SSIGN) score for clear cell renal cell carcinoma in contemporary patients. Eur Urol. 2017;71(4):665\u201373.","journal-title":"Eur Urol"},{"issue":"7","key":"4357_CR13","doi-asserted-by":"publisher","first-page":"438 e411","DOI":"10.1016\/j.urolonc.2021.04.007","volume":"39","author":"JP Blackmur","year":"2021","unstructured":"Blackmur JP, Gaba F, Fernando D, Williams S, O\u2019Donnell M, McNeill A, et al. Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinoma. Urol Oncol. 2021;39(7):438 e411-438 e421.","journal-title":"Urol Oncol"},{"issue":"3","key":"4357_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/tct.13101","volume":"17","author":"J Salem","year":"2020","unstructured":"Salem J, Fukuta J, Coombs A, Morgan J. Virtual patient journey: a novel learning resource. Clin Teach. 2020;17(3):315\u20139.","journal-title":"Clin Teach"},{"key":"4357_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1021935","volume":"13","author":"L Fu","year":"2022","unstructured":"Fu L, Bao J, Li J, Li Q, Lin H, Zhou Y, et al. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma. Front Immunol. 2022;13:1021935.","journal-title":"Front Immunol"},{"key":"4357_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.938259","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, Liu D, Chang T, Wen X, Ma S, Sun G, et al. Cuproptosis-associated lncRNA establishes new prognostic profile and predicts immunotherapy response in clear cell renal cell carcinoma. Front Genet. 2022;13:938259.","journal-title":"Front Genet"},{"issue":"8","key":"4357_CR17","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-14-2031","volume":"21","author":"L Zhang","year":"2015","unstructured":"Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, et al. Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer. Clin Cancer Res. 2015;21(8):1925\u201334.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4357_CR18","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/0008-5472.CAN-22-2224","volume":"83","author":"Z Yu","year":"2023","unstructured":"Yu Z, Lv Y, Su C, Lu W, Zhang R, Li J, et al. Integrative single-cell analysis reveals transcriptional and epigenetic regulatory features of clear cell renal cell carcinoma. Cancer Res. 2023;83(5):700\u201319.","journal-title":"Cancer Res"},{"issue":"11","key":"4357_CR19","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.humpath.2012.01.023","volume":"43","author":"J Edeline","year":"2012","unstructured":"Edeline J, Mottier S, Vigneau C, Jouan F, Perrin C, Zerrouki S, et al. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. Hum Pathol. 2012;43(11):1982\u201390.","journal-title":"Hum Pathol"},{"issue":"8","key":"4357_CR20","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/bjc.2016.263","volume":"115","author":"CM Diaz-Montero","year":"2016","unstructured":"Diaz-Montero CM, Mao FJ, Barnard J, Parker Y, Zamanian-Daryoush M, Pink JJ, et al. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model. Br J Cancer. 2016;115(8):920\u20138.","journal-title":"Br J Cancer"},{"issue":"1","key":"4357_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102741","volume":"299","author":"M Gomez-Herranz","year":"2023","unstructured":"Gomez-Herranz M, Taylor J, Sloan RD. IFITM proteins: understanding their diverse roles in viral infection, cancer, and immunity. J Biol Chem. 2023;299(1):102741.","journal-title":"J Biol Chem"},{"issue":"1","key":"4357_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.canlet.2015.07.034","volume":"368","author":"F Yu","year":"2015","unstructured":"Yu F, Xie D, Ng SS, Lum CT, Cai MY, Cheung WK, et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 2015;368(1):135\u201343.","journal-title":"Cancer Lett"},{"issue":"10","key":"4357_CR23","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1111\/cas.13640","volume":"109","author":"J Yang","year":"2018","unstructured":"Yang J, Li L, Xi Y, Sun R, Wang H, Ren Y, et al. Combination of IFITM1 knockdown and radiotherapy inhibits the growth of oral cancer. Cancer Sci. 2018;109(10):3115\u201328.","journal-title":"Cancer Sci"},{"issue":"5","key":"4357_CR24","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1158\/1541-7786.MCR-18-0916","volume":"17","author":"TE Escher","year":"2019","unstructured":"Escher TE, Lui AJ, Geanes ES, Walter KR, Tawfik O, Hagan CR, et al. Interaction between MUC1 and STAT1 drives IFITM1 overexpression in aromatase inhibitor-resistant breast cancer cells and mediates estrogen-induced apoptosis. Mol Cancer Res. 2019;17(5):1180\u201394.","journal-title":"Mol Cancer Res"},{"key":"4357_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2017.04.005","volume":"399","author":"AJ Lui","year":"2017","unstructured":"Lui AJ, Geanes ES, Ogony J, Behbod F, Marquess J, Valdez K, et al. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK\/STAT-mediated induction of p21. Cancer Lett. 2017;399:29\u201343.","journal-title":"Cancer Lett"},{"issue":"12","key":"4357_CR26","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1111\/all.14445","volume":"75","author":"OF Wirz","year":"2020","unstructured":"Wirz OF, Uzulmez O, Jansen K, van de Veen W, Lammela A, Kainulainen L, et al. Increased antiviral response in circulating lymphocytes from hypogammaglobulinemia patients. Allergy. 2020;75(12):3147\u201358.","journal-title":"Allergy"},{"key":"4357_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114442","volume":"161","author":"Q Chen","year":"2023","unstructured":"Chen Q, Shen L, Li S. Emerging role of inositol monophosphatase in cancer. Biomed Pharmacother. 2023;161:114442.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4357_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2507-z","volume":"11","author":"K Zhang","year":"2020","unstructured":"Zhang K, Liu L, Wang M, Yang M, Li X, Xia X, et al. A novel function of IMPA2, plays a tumor-promoting role in cervical cancer. Cell Death Dis. 2020;11(5):371.","journal-title":"Cell Death Dis"},{"key":"4357_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216527","volume":"582","author":"X Lei","year":"2024","unstructured":"Lei X, Liao R, Chen X, Wang Z, Cao Q, Bai L, et al. IMPA2 promotes basal-like breast cancer aggressiveness by a MYC-mediated positive feedback loop. Cancer Lett. 2024;582:216527.","journal-title":"Cancer Lett"},{"issue":"4","key":"4357_CR30","first-page":"623","volume":"55","author":"K Xie","year":"2023","unstructured":"Xie K, Liu L, Wang M, Li X, Wang B, Yin S, et al. IMPA2 blocks cervical cancer cell apoptosis and induces paclitaxel resistance through p53-mediated AIFM2 regulation. Acta Biochim Biophys Sin (Shanghai). 2023;55(4):623\u201332.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"4357_CR31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ebiom.2019.06.006","volume":"45","author":"YF Lin","year":"2019","unstructured":"Lin YF, Chou JL, Chang JS, Chiu IJ, Chiu HW, Lin YF. Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma. EBioMedicine. 2019;45:220\u201330.","journal-title":"EBioMedicine"},{"issue":"2","key":"4357_CR32","first-page":"1377","volume":"18","author":"X Liu","year":"2018","unstructured":"Liu X, Wei L, Zhao B, Cai X, Dong C, Yin F. Low expression of KCNN3 may affect drug resistance in ovarian cancer. Mol Med Rep. 2018;18(2):1377\u201386.","journal-title":"Mol Med Rep"},{"issue":"25","key":"4357_CR33","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1038\/onc.2016.501","volume":"36","author":"M Gueguinou","year":"2017","unstructured":"Gueguinou M, Crottes D, Chantome A, Rapetti-Mauss R, Potier-Cartereau M, Clarysse L, et al. The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca(2+) homeostasis. Oncogene. 2017;36(25):3640\u20137.","journal-title":"Oncogene"},{"issue":"6 Pt B","key":"4357_CR34","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.bbadis.2018.01.027","volume":"1864","author":"ZH Liu","year":"2018","unstructured":"Liu ZH, Lian BF, Dong QZ, Sun H, Wei JW, Sheng YY, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochimica et Biophysica Acta (BBA). 2018;1864(6 Pt B):2360\u20138.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"4357_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114337","volume":"183","author":"ZD Pang","year":"2021","unstructured":"Pang ZD, Wang Y, Song Z, She G, Ma XZ, Sun X, et al. AMPK upregulates K(Ca)2.3 channels and ameliorates endothelial dysfunction in diet-induced obese mice. Biochem Pharmacol. 2021;183:114337.","journal-title":"Biochem Pharmacol"},{"key":"4357_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072606","author":"O Ciesielski","year":"2020","unstructured":"Ciesielski O, Biesiekierska M, Panthu B, Vialichka V, Pirola L, Balcerczyk A. The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21072606.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"4357_CR37","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","volume":"32","author":"T Powles","year":"2021","unstructured":"Powles T, Albiges L, Bex A, Grunwald V, Porta C, Procopio G, et al. ESMO clinical practice guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511\u20139 (clinicalguidelines@esmo.org EGCEa).","journal-title":"Ann Oncol"},{"key":"4357_CR38","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, et al. (2022) Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(1):71\u201390."},{"issue":"8","key":"4357_CR39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391(8):710\u201321.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04357-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04357-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:40:00Z","timestamp":1790160000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04357-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4357"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04357-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We used summary data from publicly available databases that had obtained participant consent and ethical approval.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}